MedTrace Logo

Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis

NCT07728721 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2026-07-27

No results posted yet for this study

Summary

This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG

HSK50042 dose 1

HSK50042 taken orally once daily in the morning for 26 weeks.

DRUG

HSK50042 dose 2

HSK50042 taken orally once daily in the morning for 26 weeks.

DRUG

HSK50042 dose 3

HSK50042 taken orally once daily in the morning for 26 weeks.

DRUG

Placebo

Placebo matching HSK50042 taken orally once daily in the morning for 26 weeks.

Sponsors & Collaborators

  • Haisco Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-25
Primary Completion
2028-04-10
Completion
2028-07-25

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07728721 on ClinicalTrials.gov